Brief: Lineage Cell Therapeutics Reinitiates Patient Enrollment In Clinical Study Of Opregen

Lineage Cell Therapeutics

18/06/2020 13:08

June 18 (Reuters) - Lineage Cell Therapeutics Inc  LCTX.A :
    * LINEAGE CELL THERAPEUTICS REINITIATES PATIENT ENROLLMENT
IN
CLINICAL STUDY OF OPREGEN® FOR TREATMENT OF DRY AMD WITH
GEOGRAPHIC ATROPHY
    * LINEAGE CELL THERAPEUTICS INC - HAS RESTARTED PATIENT
ENROLLMENT
IN A PHASE 1/2A CLINICAL STUDY OF ITS LEAD PRODUCT CANDIDATE,
OPREGEN
    * LINEAGE CELL THERAPEUTICS INC - ANTICIPATES IT WILL
COMPLETE
ENROLLMENT OF LAST 3 PATIENTS IN COHORT 4 OF OPREGEN CLINICAL
STUDY IN Q3 OF 2020

Source text for Eikon:  ID:nBw8FN4KXa 
Further company coverage:  LCTX.A 

 ((Reuters.Briefs@thomsonreuters.com;))